Release Date: June 5, 2022
Expiration Date: June 30, 2022
Activity Overview
This educational activity is an archive of the live virtual presentation held on June 4, 2022.
For more information about this educational activity, the faculty, and disclosures, please click here.
Target Audience
This educational activity is directed toward physicians involved in the treatment of prostate cancer.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Explain clinical trial data and evidence-based recommendations for the management of non-metastatic and metastatic forms of CRPC
- Determine strategies to optimize sequencing of current therapies in the care of patients with CRPC
- Assess recent trial evidence from studies that evaluated novel approaches for CRPC in the context of their impact on evolving paradigms in the field
- Apply proactive strategies to monitor for and manage treatment-associated toxicities in CRPC care settings
Robert Dreicer, MD, MS, MACP, FASCO
Professor of Medicine and Urology
University of Virginia School of Medicine
Section Head, Medical Oncology
Associate Director for Clinical Research
Deputy Director, University of Virginia Cancer Center
Co-Director, Paul Mellon Urologic Cancer Institute
Professor of Medicine and Urology
University of Virginia School of Medicine
Charlottesville, VA
Disclosures: Consultant: Astellas, AstraZeneca, Aveo, Bayer, BMS, Exelixis, EMD Serono, Gilead, Hengrui, Hinova, Janssen, Merck, Myovant, Pfizer, Propella, Sanofi Genzyme, Seattle Genetics, Tavanta.
Tomasz Beer, MD, FACP
Professor of Medicine, Division of Hematology/Medical Oncology
Grover C. Bagby
Chair of Prostate Cancer Research
OHSU Knight Cancer Institute Deputy Director
OHSU Knight Cancer Institute
Chief Medical Officer
CEDAR, OHSU Knight Cancer Institute
Oregon Health & Science University, School of Medicine
Portland, OR
Disclosures: Grant/Research Support: Funding Paid to Institution: Alliance Foundation Trials, Astellas Pharma, Bayer, Boehringer Ingelheim, Corcept Therapeutics, Endocyte Inc., Exact Sciences Corp., Freenome, Grail Inc., Harpoon Therapeutics, Janssen Research & Development, Medivation Inc., Merck, Sotio, Theraclone Sciences/OncoResponse, Zenith Epigenetics; Consultant: AbbVie, Amgen, Arvinas, Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squib, Constellation, Dantari Pharmaceuticals, GlaxoSmithKline (GSK), Grail Inc., Janssen, Myovant Sciences, Pfizer, Sanofi, Sapience Therapeutics; Stock/Shareholder: Arvinas Inc., Salarius Pharmaceuticals.
Scott Tagawa, MD, MS, FACP
Professor of Medicine & Urology
Medical Director, Genitourinary Oncology Research Program
Weill Cornell Medicine
New York, NY
Disclosures: Grant/Research Support: Sanofi, Medivation, Astellas, Janssen, Amgen, Progenics, Dendreon, Lilly, Genentech, Newlink, BMS, Inovio, AstraZeneca, Immunomedics, Aveo, Rexahn, Atlab, Boehringer Ingelheim, Millennium, Bayer, Merck, AbbVie, Karyopharm, Endocyte, Clovis, Seattle Genetics, Novartis, Gilead, POINT Biopharma; Consultant: Sanofi, Medivation/Astellas, Dendreon, Janssen, Genentech, Bayer, Endocyte, Eisai, Immunomedics, Karyopharm, AbbVie, Tolmar, Seattle Genetics, Amgen, Clovis, QED, Pfizer, AAA/Novartis, Clarity, Genomic Health, POINT Biopharma, Blue Earth Diagnostics, AIkido Pharma, Telix Pharma, Convergent Therapeutics, EMD Serono; Stock/Shareholder: Alkido.
Tanya Dorff, MD
Section Chief, Genitourinary Disease Program
Associate Professor, Department of Medical Oncology & Therapeutics Research
City of Hope
Duarte, CA
Disclosures: Consultant: SeaGen, Exelixis, AstraZeneca, Pfizer, Astellas, Janssen.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
